（文章来源：证券日报） 证券日报网讯 2月25日，华兰生物发布公告称，公司参股公司华兰安康生物股份有限公司收到国家药监 局《药物临床试验批准通知书》，帕博利珠单抗注射液获准按生物类似药开展临床试验，用于黑色素 瘤、非小细胞肺癌、食管癌、头颈部鳞状细胞癌等适应症。 ...

Core Viewpoint - Hualan Biological Engineering Co., Ltd. announced that its subsidiary, Hualan Ankang Biopharmaceutical Co., Ltd., received approval for clinical trials of its biosimilar drug, Pembrolizumab injection, marking a significant step in expanding its product pipeline and optimizing product structure [1][2]. Group 1 - Hualan Ankang has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing it to officially conduct clinical research on Pembrolizumab injection [1]. - Pembrolizumab is a humanized monoclonal antibody targeting the PD-1 immune checkpoint, which plays a crucial role in tumor immune evasion by inhibiting T cell activity [1]. - The original product, Keytruda, developed by Merck, is one of the first PD-1 inhibitors approved globally for various significant cancer indications, including non-small cell lung cancer and melanoma [1]. Group 2 - The approval of clinical trials for Pembrolizumab injection signifies the drug's potential to further validate its safety and efficacy, laying the groundwork for future registration and market launch [2]. - Currently, there are no similar drugs approved for marketing in China, highlighting the competitive advantage for Hualan Ankang in the biosimilar market [2].

公告显示，帕博利珠单抗是一种靶向程序性死亡受体-1(PD-1)的人源化单克隆抗体。PD-1是免疫T细胞 表面的一种关键免疫检查点蛋白，肿瘤细胞可通过激活PD-1通路抑制T细胞的免疫活性，从而实现免疫 逃逸。帕博利珠单抗通过阻断PD-1与其配体PD-L1/PD-L2的结合，恢复T细胞的肿瘤杀伤功能，增强人 体免疫系统对抗肿瘤的能力。该药物作为免疫检查点抑制剂，已成为多种晚期恶性肿瘤的标准治疗方案 之一，革新了肿瘤治疗格局。 智通财经APP讯，华兰生物(002007.SZ)公告，公司参股公司华兰安康生物股份有限公司收到国家药品监 督管理局《药物临床试验批准通知书》，帕博利珠单抗注射液获同意按生物类似药开展临床试验。 ...

Core Viewpoint - Hualan Biological (002007.SZ) announced that its associate company, Hualan Ankang Biological Co., Ltd., received the Clinical Trial Approval Notification from the National Medical Products Administration for the clinical trial of Pembrolizumab injection as a biosimilar [1] Group 1: Company Information - Hualan Ankang Biological Co., Ltd. is advancing the clinical trial of Pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) [1] - The drug Pembrolizumab is designed to block the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring the tumor-killing function of T cells and enhancing the immune system's ability to combat tumors [1] Group 2: Industry Context - Pembrolizumab, as an immune checkpoint inhibitor, has become a standard treatment option for various advanced malignancies, revolutionizing the landscape of cancer treatment [1]

格隆汇2月25日｜华兰生物(002007.SZ)公告称，公司参股公司华兰安康收到国家药品监督管理局《药物 临床试验批准通知书》，同意帕博利珠单抗注射液按生物类似药开展临床试验。帕博利珠单抗注射液为 生物类似药，由默沙东公司开发，是全球首个获批上市的PD-1抑制剂之一。目前国内除原研外，暂未 有类似药获批上市。本次临床试验获批，标志着药物可正式开展对应临床研究，进一步验证安全性与有 效性，为后续注册上市奠定基础，同时丰富公司产品管线，优化产品结构。但药品研发具有周期长、环 节多、风险高的特点，后续尚需完成全部临床试验、生产申报、国家药监局审批等环节，各环节结果均 存在不确定性；同时面临临床数据与进度不及预期、市场竞争激烈、行业政策及技术迭代变化等风险。 ...

证券日报网讯 12月16日，华兰生物发布公告称，近日参股公司华兰基因工程有限公司收到国家药品监 督管理局签发的帕博利珠单抗注射液境内生产药品注册临床试验申请《受理通知书》（受理号： CXSL2501079）。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Gene Engineering Co., Ltd., received a clinical trial application acceptance notice from the National Medical Products Administration for the domestic production of Pembrolizumab injection [1] - Pembrolizumab is a biosimilar drug developed by the company, targeting multiple cancers including melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1] - The original product of Pembrolizumab, marketed as Keytruda, was developed by Merck and is one of the first PD-1 inhibitors approved globally, recognized for its clinical value across various significant tumor indications [1] Group 2 - Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), which plays a crucial role in immune checkpoint regulation [2] - The drug works by blocking the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring T cell anti-tumor activity and enhancing the immune system's ability to combat tumors [2] - As an immune checkpoint inhibitor, Pembrolizumab has become a standard treatment for various advanced malignancies, revolutionizing the landscape of cancer treatment [2] - Currently, there are no similar drugs approved for marketing in China, aside from the original product [2]

Core Viewpoint - Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Gene Engineering Co., Ltd., received a clinical trial application acceptance notice from the National Medical Products Administration for the domestic production of the drug Pembrolizumab injection [1] Group 1: Drug Development - The Pembrolizumab injection developed by the company is a biosimilar drug [1] - The original product of Pembrolizumab (brand name: Keytruda) was developed by Merck & Co. and is one of the first PD-1 inhibitors approved globally [1] - Pembrolizumab has been approved for multiple significant cancer indications, including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, esophageal cancer, liver cancer, gastric cancer, and colorectal cancer [1] Group 2: Mechanism of Action - Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) [1] - PD-1 is a critical immune checkpoint protein on the surface of immune T cells, which tumor cells can activate to suppress T cell immune activity, leading to immune evasion [1] - Pembrolizumab works by blocking the binding of PD-1 to its ligands PD-L1/PD-L2, restoring T cell tumor-killing function and enhancing the immune system's ability to combat tumors [1] Group 3: Market Impact - As an immune checkpoint inhibitor, Pembrolizumab has become one of the standard treatment options for various advanced malignancies, revolutionizing the landscape of cancer treatment [1]

华兰生物公告，近日，公司参股公司华兰基因工程有限公司收到国家药品监督管理局签发的帕博利珠单 抗注射液境内生产药品注册临床试验申请《受理通知书》（受理号：CXSL2501079）。药品名称为帕 博利珠单抗注射液，申请事项为境内生产药品注册临床试验，注册分类为治疗用生物制品3.3类，规格 为100mg（4ml）/瓶，药品适应症为黑色素瘤、非小细胞肺癌、食管癌、头颈部鳞状细胞癌等。 ...

Core Viewpoint - Junshi Bioscience plans to raise approximately HKD 1.039 billion through the placement of 41 million new H-shares at a price of HKD 25.35 per share, which represents an 11.52% discount to the closing price on June 12 [1] Group 1: Fundraising and Use of Proceeds - The company intends to allocate 70% of the raised funds for innovative drug development, focusing on dual-specific antibodies such as JS207 (PD-1/VEGF), JS212 (EGFR/HER3), and JS213 (PD-1/IL-2) [1] - The remaining funds will be used to supplement working capital [1] - Junshi Bioscience previously announced an investment of CNY 767 million in the PD-1/VEGF dual antibody (JS207) [1] Group 2: Clinical Development and Market Position - JS207 is currently in Phase II clinical trials, with plans to conduct key clinical trials for lung cancer, breast cancer, liver cancer, colorectal cancer, and other advanced solid tumors [1] - Junshi Bioscience, established in December 2012, was the first domestic company to receive approval for a PD-1 monoclonal antibody, but its product, Toripalimab, has faced stiff competition from later entrants [4] - Toripalimab remains the company's leading product, generating CNY 1.501 billion in domestic sales in 2024, accounting for 77% of total revenue of CNY 1.948 billion [4] Group 3: Financial Performance and Market Trends - Despite not yet achieving profitability, the company's losses have significantly narrowed in 2024, with Q1 revenue and net loss reported at CNY 500 million and CNY 235 million, respectively [4] - The PD-1/VEGF dual antibody field has gained traction, with significant competitive developments, including a head-to-head trial where a competitor's product outperformed the leading PD-1 drug [5] - The innovative drug sector has seen a strong performance in the A-share market, with a 12.72% increase in May and a total increase of over 22% from April to June [6]